Citigroup
MBRX icon

Citigroup’s Moleculin Biotech MBRX Stock Holding History

Citigroup’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.46K Buy
+2,674
New +$6.83K ﹤0.01% 5274
2025
Q3 		– Sell
-3,411
Closed -$25.7K – 6227
2025
Q2 		$25.7K Buy
3,411
+3,299
+2,946% +$67.6K ﹤0.01% 5018
2025
Q1 		$2.71K Buy
+112
New +$3.76K ﹤0.01% 5330
2017
Q1 		– Sell
-3
Closed -$17K – 7270
2016
Q4 		$17K Buy
3
+1
+50% +$6.7K ﹤0.01% 6592
2016
Q3 		$29K Hold
2
– – ﹤0.01% 6007
2016
Q2 		$33K Buy
+2
New +$32.3K ﹤0.01% 5836

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM

Citigroup's MBRX Position: Q2 2026 in Review

Citigroup opened a new position in Moleculin Biotech (MBRX) in Q2 2026: 2,674 shares worth $7.46K. The stake represents ﹤0.01% of the portfolio and ranks #5274 among its holdings. This is a return to the name: Citigroup previously reported a position in MBRX as recently as Q2 2025.

Citigroup first reported a position in MBRX in Q2 2016 and has held it in 6 quarters since. The position peaked at $33K in Q2 2016. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Citigroup held 2,674 shares of Moleculin Biotech worth $7.46K as of Q2 2026.
  • Moleculin Biotech was a new Citigroup position in Q2 2026.
  • Moleculin Biotech made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5274 holding.
  • Citigroup first reported a position in Moleculin Biotech in Q2 2016 and has held it in 6 quarters since.
  • Citigroup's Moleculin Biotech position peaked at $33K in Q2 2016.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.